Board Meeting14 Nov 2026, 07:03 pm
Aarey Drugs Declares Unaudited Q2 FY27 Results
AI Summary
Aarey Drugs & Pharmaceuticals Ltd announced its un-audited standalone financial results for the second quarter and half-year ended September 30, 2026. The board of directors approved these results along with the Limited Review Report and MD/CFO certification. Additionally, the company approved a Statement of Deviation or Variation in the Utilization of Funds Raised through Convertible Warrants (Preferential Issue). The trading window will reopen 48 hours after the announcement of these results.
Key Highlights
- Board meeting held on November 14, 2026.
- Approved un-audited standalone financial results for Q2 & HY ended Sep 30, 2026.
- Reviewed and approved Statement of Deviation/Variation in fund utilization.
- Trading window to open 48 hours post-announcement.
Price Impact
More from AAREYDRUGS